Sciences
Life sciences, biotech, and research innovation.
Create content from your team’s expertise with free recording and AI writing tools. Qualifying companies also get one professional video edit a month. No credit card.
Antibody developability checks are moving into discovery instead of waiting for development
FairJourney Bio's Maria Gonzalez-Pajuelo says developability has become a much more important consideration during antibody discovery.
All Articles
Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting
ISPE’s 2026 Annual Meeting chairs explain why AI has no track of its own—and why they expect it to show up across the five tracks, from discovery to governance.
Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse
Crown Bioscience's San Diego CRO designs preclinical oncology models to match specific therapies, including orthotopic brain tumors and post-treatment PDX…
Clinical data harmonization is the bottleneck for life sciences AI
Commentary argues life sciences AI hinges on clean, harmonized trial data that’s ready for machine learning pipelines—not just better models.
CDMOs’ new capacity skews stainless by liters, but single-use leads by system count
BDO’s bioTRAK data shows CDMOs plan about 120 new bioreactors by 2030: 71% of added liters are large-scale stainless steel, but 61% of systems are single-use.
Pharma supplier diversification means little if every supplier uses the same airport
Biocair's Patrick Wohl argues pharma supply maps must cover airports, sea lanes and carriers, since suppliers in different countries can share one hub.
Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Eli Lilly are expanding their strategic partnership, which began in 2023, with a series of substantial investments aimed at bolstering U.S. pharmaceutical manufacturing. The collaboration, marked by a $750 million investment, focuses on increasing the production of Lilly’s KwikPen®, a
ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%
A 35-day AI run at ENEOS’ Yokkaichi butadiene unit is becoming the autonomy benchmark. The hard part now is data plumbing, governance, and where agents fit.
Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration
Novaspace projects 6,500+ EO satellites through 2035 and $155.9B in manufacturing revenue. For operators, standard buses and multi-sensor payloads shift risk to
Samsung Biologics reports $262M manufacturing deal running through 2033
Samsung Biologics disclosed a $262 million manufacturing deal with an undisclosed European pharmaceutical company that runs through 2033.
Robotic Systems Emerge for Cell and Gene Therapy Manufacturing
A 2024 Cytotherapy study describes a robotic cluster built to automate manual cell therapy manufacturing steps.
Deloitte's Biopharma AI Value Estimates Come With a Timing Catch
Deloitte estimated top biopharma firms could capture $5-7B in AI value. McKinsey and ISPE material show why timelines and validation still lag.
CPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connector
CPC Biotech and Multiply Labs announced a robot-optimized aseptic connector for closed cell therapy manufacturing systems.
Lab automation ROI hinges on integration, not instrument sensitivity claims
Waters’ “5x greater sensitivity” claim and LabCollector’s ELN/LIMS AI Co-Scientist point to the same constraint in lab automation: the handoffs, instrument to m
AeroVironment to co-design three autonomous helicopters for NASA's SkyFall Mars mission
AeroVironment’s MacCready Works won work on three autonomous Mars helicopters for NASA’s SkyFall, putting aerospace-grade autonomy, avionics integration, and re
Telehealth "digital waiting rooms" are turning into premium pharma ad slots
New patient-attention data and agency execution details are pushing pharma media plans toward pre- and post-visit virtual care moments.
Roche pTau217 clearance and Labcorp’s Alzheimer’s test bring diagnostics to primary care
New Alzheimer’s pathology tests and lab automation are shifting the bottleneck from assay availability to workflow activation.
Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031
Genentech will spend $750 million on a Hillsboro device fill-finish plant for prefilled syringes and autoinjectors, targeting commercial operations in 2031 and creating 250 manufacturing jobs.
4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%
Genezen will offer 4basebio’s cell-free hpDNA as starting material for viral vectors, a shift that could change how programs specify plasmids, timelines, and CO
Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt
Bristol Myers ended its deal with Cellares, a reminder that cell therapy supply plans still hinge on process fit, not just factory slots.
Argonne’s AI agents push materials R&D toward days-long cycles
Argonne’s new agentic workflows suggest a procurement shift: buy for dataflow and security, not bigger models.
Cancer diagnostics growth is forcing labs to budget for data, not just instruments
MarketsandMarkets forecasts cancer diagnostics will grow from $29.86B in 2026 to $44.92B by 2031. Frost & Sullivan says the constraint is operational: staffing,
Wall Street is split on Circle: TD Cowen sees 31% upside while Morgan Stanley sees 39% downside
TD Cowen initiated Circle with a buy and an $82 target; Morgan Stanley slashed its target to $38, calling stablecoin utility overstated.
Sony and TSMC's $6.3 billion image-sensor bet signals a new era of chip co-investment
Sony and TSMC plan to spend $6.3B jointly on next-gen image-sensor chips, as AI demand reshapes semiconductor supply chains in 2026.
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…
What Exactly Is a 5-Log Reduction, and Why Does It Matter for Cleanroom Teams
In cleanroom environments, contamination control isn’t about vague cleanliness—it’s about measurable reductions, and a 5-log reduction means cutting microbial presence by 99.999%, turning 100,000 bacteria into just one. For cleanroom teams, this level of performance before disinfectants are even applied is critical, because it dramatically lowers bioburden risk and strengthens the effectiveness of every…
My Biggest Takeaway from NC State’s Bioprocessing Course
Hands-on immersion has become a defining advantage in modern biomanufacturing, and programs like NC State’s BTEC exemplify why experiential learning matters as much as technical knowledge. By stepping through a full upstream and downstream bioprocess in a simulated environment, the Benchmark team gained firsthand insight into the real-world pressures, decisions, and constraints their customers…
Lamar IoT’s Cutting-Edge Tracking Tech Prevents Drugs & High-End Food Products from Perishing
Real-time condition monitoring prevents costly losses of temperature-sensitive pharmaceuticals and perishables across complex global supply chains
From the archive
Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026
At Paris Packaging Week 2026, Tekniplex didn’t just exhibit—it staged an experience that reflected the evolving intersection of materials science and brand storytelling. The company’s modern booth, complete with a living wall and immersive digital displays, signaled a broader shift in how packaging innovators are choosing to engage a sustainability-conscious audience. Beneath the…
Oscar Martin Interview – AMI Single Serve Tampa – 2026
The single-serve coffee industry is at a pivotal moment, where convenience and sustainability are no longer competing priorities but parallel expectations shaping innovation. At gatherings like the AMI Single Serve Coffee Conference in Tampa, the conversation has clearly shifted from abstract goals to tangible, commercially viable solutions—especially in the realm of compostable and recyclable…
What the Future Looks Like if We Get It Right
As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…
New to MarketScale?
MarketScale is the B2B media platform Sciences companies use to publish their own experts. Create a free workspace with no credit card, or book a demo to see how it works for your team.